Nanobiotix announces ?2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication
(Thomson Reuters ONE) -
Through ETPN (European Technology Platform of Nanomedicine), Nanobiotix is
driving nanomedicine in Europe and is now involved in the first nanomedicine
consortium in France with the launch of NICE project
Paris, France, 3 July, 2013 - NANOBIOTIX (Euronext: NANO), a clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer, announces today it has secured c.?9 million in funding from bpifrance
(formerly OSEO) of which ?2.8 million is directly attributable to the Company.
This grant, awarded through bpifrance's Strategic Industrial Innovation (ISI)
program, will accelerate the clinical and industrial development of the
Company's lead product NBTXR3 in a new indication, liver cancer (hepatocellular
carcinoma). Liver cancer is a major health problem that causes one of the
greatest number of deaths each year worldwide, c.695,000 deaths per annum.
This grant supports the launch of NICE (Nano Innovation for CancEr), the first
consortium of nanomedicine stakeholders in France focused on characterization
and industrialization aspects. The consortium has been accredited by the Medicen
Paris Region, a competitive cluster for innovative therapies in Ile-de-France
(www.medicen.org).
Consisting of five public and private partners, the NICE consortium includes
partners with in depth expertise in the field of nanomedicine. Its mission is to
build a platform to accelerate the development and industrialization of
nanomedicine in France by capitalizing on the strong and complementary expertise
of each partner.
Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical
development for advanced soft tissue sarcoma and has received authorization from
the French Medicine Agency, ANSM, to start a second clinical trial in patients
with locally advanced cancers of the oral cavity or oropharynx (head and neck
cancer). NBTXR3 will benefit fully from this platform of expertise and funding
received from bpifrance by being able to accelerate its clinical development.
The purpose of this project is the start of a new Phase I clinical study with
NBTXR3 in patients with primary liver cancer.
In addition to Nanobiotix, the consortium includes BioAlliance Pharma, leader of
the consortium which is developing Livatag®, a doxorubicin nanoparticle
currently in Phase III clinical trial for treatment of primary liver cancer;
CEA-Leti, the developer of cancer-detecting nanoparticles based on Leti's
Lipidots® platform; DBI, a company specialized in the production of nanomedicine
pharmaceutical products and the Institut Galien Paris Sud (University Paris
Sud/CNRS), which has an academic-excellence team specialized in nanoparticle
research.
"Today, nanomedicine is considered as one of the major growth drivers of the
global pharmaceutical industry and it is essential that the industry is
structured at the local level to be competitive," said Laurent Levy, CEO of
Nanobiotix. "In turn, Nanobiotix will benefit from the consortium in two ways;
if the sector is structured right to be able to accelerate the development and
industrialization of products, and in the development of a new indication of
NBTX3 which will help patients and build shareholder value."
-ENDS-
About BPIFRANCE's Strategic Industrial Innovation (ISI) program
The Strategic Industrial Innovation program promotes the emergence of European
champions. It supports ambitious, innovative collaborative projects through to
industrialization, driven by innovative medium-sized companies (less than 5000
employees) and small businesses (less than 250 employees). These highly
promising projects are aimed at the commercialization of products which result
from technological breakthroughs and which not be possible without fostering
measures from the public sector. Funding is generally in the ?3-10 million
range, as grants-in aid and loans which are repayable if the project is a
success.
About NANOXRAY
Nanobiotix's first-in-class, proprietary technology called NanoXray is at the
forefront of a new era of nanomedicine, where nanoparticles are not just a
vehicle for targeted drug delivery, but have become the principal active
element. The NanoXray technology is based on the physical properties of hafnium-
oxide nanoparticles and is used to enhance the efficacy of radiotherapy
treatment for a variety of cancer indications.
Nanoparticles are designed to enter tumor cells and, upon activation by a
standard dose of radiation, they emit large amounts of electrons resulting in
the generation of free radicals that destroy cancer cells (the same mode of
action than radiotherapy but largely amplified). Nanoparticle-enhanced
radiotherapy therefore amplifies the lethal dose of energy locally within the
tumor without changing the effect of the dose passing through surrounding
healthy tissues.
By changing the coating of the nanoparticles, Nanobiotix is developing three
different products that can be administered either by direct injection into the
tumor (NBTXR3), intravenous injection (NBTX-IV) or topical application to fill
tumor cavities after surgery (NBTX-TOPO). The product applied will depend on
type of tumor and the patient's specific clinical needs. NanoXray products are
classified as a medical device in Europe and as a drug in the US. They are
compatible with current radiotherapy methods with respect to equipment and
protocols, as well as with older radiotherapy equipment or any radiation-based
therapy.
About NANOBIOTIX
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage
nanomedicine company pioneering novel approaches for the local treatment of
cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances
radiotherapy energy to provide a new, more efficient treatment for cancer
patients. NanoXray products are compatible with current radiotherapy treatments
and are meant to treat a wide variety of cancers via multiple routes of
administration. Nanobiotix's lead product NBTXR3, based on NanoXray, is
currently under clinical development for soft tissue sarcoma. The Company has
partnered with PharmaEngine for clinical development and commercialization of
NBTXR3 in Asia. The Company is based in Paris, France.
Laurent Levy, CEO and co-founder of Nanobiotix, is the Vice-President of the
European Technology Platform of Nanomedicine (ETPN).
For more information, please visit www.nanobiotix.com
For more information, please contact:
Nanobiotix Yucatan
Laurent Levy Media relations (France)
CEO Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)1 40 26 07 55 +33 (0)1 53 63 27 27 / +33 (0)6
laurent.levy(at)nanobiotix.com 88 20 35 59
afloyer(at)yucatan.fr
NewCap. College Hill
Financial communication Media relations (Outside France)
and investors relations Melanie Toyne Sewell / Donia Al Saffar
Louis-Victor Delouvrier / Emmanuel +44 (0) 207 457 2020
Huynh nanobiotix(at)collegehill.com
+33 (0)1 44 71 98 53
lvdelouvrier(at)newcap.fr
bpifrance
Vanessa Godet
+33 (0)1 41 79 84 33
vanessa.godet(at)oseo.fr
Delphine Peyrat-Stricker
+33 (0)6 38 81 40 00
Press Release (PDF):
http://hugin.info/157012/R/1714109/569130.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: NANOBIOTIX via Thomson Reuters ONE
[HUG#1714109]
Datum: 03.07.2013 - 18:35 Uhr
Sprache: Deutsch
News-ID 275549
Anzahl Zeichen: 9135
contact information:
Town:
Paris
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 281 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nanobiotix announces ?2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication"
steht unter der journalistisch-redaktionellen Verantwortung von
NANOBIOTIX (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
